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Abstract
Human genetic background strongly influences susceptibility to malaria infection and progression to severe disease and
death. Classical genetic studies identified haemoglobinopathies and erythrocyte-associated polymorphisms, as protective
against severe disease. High throughput genotyping by mass spectrometry allows multiple single nucleotide
polymorphisms (SNPs) to be examined simultaneously. We compared the prevalence of 65 human SNP’s, previously
associated with altered risk of malaria, between Tanzanian children with and without severe malaria. Five hundred children,
aged 1–10 years, with severe malaria were recruited from those admitted to hospital in Muheza, Tanzania and compared
with matched controls. Genotyping was performed by Sequenom MassArray, and conventional PCR was used to detect
deletions in the alpha-thalassaemia gene. SNPs in two X-linked genes were associated with altered risk of severe malaria in
females but not in males: heterozygosity for one or other of two SNPs in the G6PD gene was associated with protection
from all forms of severe disease whilst two SNPs in the gene encoding CD40L were associated with respiratory distress. A
SNP in the adenyl cyclase 9 (ADCY9) gene was associated with protection from acidosis whilst a polymorphism in the IL-1a
gene (IL1A) was associated with an increased risk of acidosis. SNPs in the genes encoding IL-13 and reticulon-3 (RTN3) were
associated with increased risk of cerebral malaria. This study confirms previously known genetic associations with protection
from severe malaria (HbS, G6PD). It identifies two X-linked genes associated with altered risk of severe malaria in females,
identifies mutations in ADCY9, IL1A and CD40L as being associated with altered risk of severe respiratory distress and
acidosis, both of which are characterised by high serum lactate levels, and also identifies novel genetic associations with
severe malaria (TRIM5) and cerebral malaria(IL-13 and RTN3). Further studies are required to test the generality of these
associations and to understand their functional consequences.
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Introduction
In spite of recent evidence of successful control in some
countries [1,2,3], malaria still constitutes a major cause of child
morbidity and mortality, especially in sub Saharan Africa [4,5].
Although the number of deaths from malaria remains high, the
absolute risk of any particular infection progressing to severe
disease is less than 1%, even in young children who appear to have
similar, often low, levels of acquired immunity [6]. The risk factors
for severe disease, and the reasons for the wide variation in clinical
manifestations of malaria among children who appear to exhibit
similar risks for severe disease, are poorly understood. This
unexplained variation in disease severity and syndromic pheno-
type constitutes a major challenge to our understanding of the
disease, its treatment and control.
Although parasite diversity, host age, acquired immunity and
overall health status may all influence the risk of severe disease
complications, it has been estimated that 25% of this risk can be
accounted for by variations in host genotype [7]. The different
geographic distributions of sickle-cell disease, a-thalassaemia,
glucose-6-phosphate dehydrogenase (G6PD) deficiency, ovalocy-
tosis, and the Duffy-negative blood group are examples of the
general principle that different populations have evolved different
genetic variants to protect against malaria (see [8] for a review).
The most striking example is the beta-globin HBB gene, in which
three different coding SNPs confer protection against malaria:
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Glu6Val (HbS), Glu6Lys (HbC), and Glu26Lys (HbE). The HbS
allele is common in Africa but rare in Southeast Asia, whereas the
opposite is true for the HbE allele. In Tanzania, strong
associations have been described between malaria transmission
intensity and polymorphisms of both the HbS and alpha-
thalassaemia genes [9]. In addition to the sickle polymorphism
(HbS) [10], G6PD (reviewed in [11]), and ABO blood group
[12,13], a number of other traits have been proposed for the
reduced risk of severe malaria. Consistent with the view that severe
malaria disease is, at least in part, an inflammatory process
mediated by disordered immune responses [14] many of these
traits are polymorphisms in genes that are relevant to immunity
and inflammation such as the tumor necrosis factor (TNF, MHC
class III region, reviewed in [15], Toll-like receptors (TLR-4,9)
[16], CD40 ligand (CD40L) [17], the interferon gamma (IFNG)
(reviewed in [18]), and the Nitric oxide synthase type 2 (NOS2A)
genes (reviewed in [19]).
Here we test a panel of 65 SNPs, previously linked to altered risk
of malaria or other infectious diseases, including the HbS and
ABO polymorphisms, for association with severe malaria, and
with the various clinical presentations of severe malarial disease.
Our study is the first to comprehensively survey candidate SNPs in
Tanzanians resident in a hyperendemic area of malaria with a
high incidence of severe malaria disease and reveals X-linked
polymorphisms that affect risk of severe disease in females but not
in males, as well as polymorphisms in genes associated with
inflammation, antigen processing and T cell function.
Methods
Ethics Statement
All DNA samples were collected and genotyped following
signed and informed written consent from a parent or guardian.
Ethics approval for all procedures was obtained from both
LSHTM (# 2087) and the Tanzanian National Institute of
Medical Research (NIMR/HQ/R.8a/Vol. IX/392).
Participants, Materials and Methods
Study participants. The study was conducted in Teule
district hospital, Muheza, and surrounding villages in Muheza
district, Tanga region, Tanzania, where mortality in children
under 5 is estimated at 165 per 1000 (Tanzanian census 2002).
Transmission of P. falciparum is intense (50–700 infected bites/
person/year) and perennial, with two seasonal peaks. The
community prevalence of P. falciparum in children aged 2–5 years
in the study area was recorded as 88.2% in 2002 [20].
Cases were recruited during a one-year period between June
2006 and May 2007 as part of a larger study of severe febrile
illness in children [detailed in [21,22]]. Among the children in the
parent study, 509 cases of severe malaria were randomly sampled
from children aged 6 months to 10 years meeting any one of the
following eligibility criteria; history of 2 or more convulsions in the
previous 24 hrs, prostration (unable to sit unsupported if ,9
months of age or unable to drink at any age), reduced
consciousness (Blantyre Coma scale,4), respiratory distress (deep
breathing or indrawing of the lower chest wall), visible jaundice,
severe anaemia (Hb ,5 g/dL), acidosis (blood lactate $5 mmol/
L) or hypoglycaemia (blood glucose ,2.5 mmol/L). Parasite
infection was confirmed by microscopic examination of Giemsa-
stained thick blood films by two independent microscopists.
Participants with known chronic medical conditions were exclud-
ed. Area of residence and ethnic origins of both parents were
recorded from information provided by the caretaker of each
child.
Controls were recruited during a 4 week period in August 2007
and were matched with cases for area of residence (ward), ethnicity
and age, using household census data. Study participants resided
in 33 wards surrounding Muheza town. The participants had a
median age of ,2.6 years and belonged, predominantly, to one of
eight ethnic groups (Table 1).
Sample collection & preparation. Approximately 3 ml of
venous blood was collected from each participant into an EDTA
vacutainer. A blood film was prepared and haemoglobin levels
were measured by Hemocue (HemocueTM, Anglholm, Sweden).
For children in the control group, those with haemoglobin levels of
,11 g/dL and those with a positive blood film were excluded
from genetic analysis and were referred to the nearest health
Table 1. Baseline and clinical characteristics of cases and
controls.
Controls (n=480) Cases (n =507)
Age* (median, range) (2.9) (0.9–10.9) (1.7) (0.2–10.0)
Gender - Female 258 53.8% 236 46.5%
Ward
Mtindiro 40 8.3% 49 9.7%
Kwafungo 32 6.7% 43 8.5%
Mkata 32 6.7% 32 6.3%
Kwedizinga 30 6.3% 31 6.1%
Songa 25 5.2% 25 4.9%
Nkumba 21 4.4% 27 5.3%
Segera 23 4.8% 23 4.5%
Maramba 22 4.6% 21 4.1%
Mhinduro 20 4.2% 20 3.9%
Potwe 20 4.2% 20 3.9%
Kilulu 19 4.0% 19 3.7%
Lusanga 18 3.8% 18 3.6%
Kicheba 15 3.1% 18 3.6%
Ngomeni 16 3.3% 16 3.2%
Ethnicity
Mzigua 159 33.1% 149 29.4%
Wasambaa 132 27.5% 131 25.8%
Wabondei 78 16.3% 79 15.6%
Chagga 50 10.4% 47 9.3%
Mmbena 23 4.8% 25 4.9%
Other 5 1.0% 39 7.7%
Mngoni 18 3.8% 19 3.7%
Pare 15 3.1% 18 3.6%
Clinical phenotype
Any severe malaria - - 507 100%
Any SMA** - - 247 48.7%
Any CM - - 99 19.5%
Both SMA+CM - - 41 8.1%
Any RD - - 146 28.8%
Acidosis*** - - 291 57.4%
*in months, SMA= severe malarial anaemia, CM= cerebral malaria,
RD= respiratory distress,
**hb,5 gdl,
***Blood lactate.5 mmol/l.
doi:10.1371/journal.pone.0047463.t001
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facility where they were treated according to Tanzanian Ministry
of Health guidelines. Samples were centrifuged at 5000 rpm for
5 minutes and the plasma removed and stored for future analysis.
DNA was extracted and purified from the blood cell pellet using a
Nucleon kit (http://www.tepnel.com) according to the manufac-
turer’s instructions.
Sample genotyping. Genomic DNA samples underwent
whole genome amplification through either Primer Extension
Pre-amplification (PEP) [23]or Multiple Displacement Amplifica-
tion (MDA) [24], before genotyping on a Sequenom MassArray
genotyping platform [25,26]. Sixty-five candidate SNPs (see
supplementary Table 1) were selected for typing based on an
extensive review of the published data and on emerging data from
the MalariaGEN consortium (http://www.malariagen.net). The
selected SNPs included Haemoglobin variant S (HbS) (rs334) as an
anticipated positive control. The a3.7-thalassaemia deletion was
typed separately by PCR [27].
Phenotypic definition. For analysis, subjects were defined as
having had cerebral malaria (CM) if their Blantyre coma score was
less than 3 on presentation to hospital. A second phenotypic subset
of severe malarial anaemia (SMA) was defined as those subjects
having had a haemoglobin concentration of less than 5 g/dL.
Patients with both CM and SMA were included in the analysis for
both phenotypes. Participants with co-existing severe illnesses
diagnosed on admission, or with known chronic medical
conditions unrelated to a severe malarial infection, were excluded.
Other phenotypes of interest in severe malaria cases included
respiratory distress and acidosis (blood lactate greater than
.=5 mmol/L). Because of sample size limitations, we do not
present an analysis by ethnic groups or ward of residence.
Statistical analysis. Genotypic deviations from Hardy-
Weinberg equilibrium (HWE) were assessed by chi-square tests.
SNPs were excluded from analysis if they had at least 10% of
genotype calls missing or there was significant deviation from
HWE (p,0.001) in controls. Case-control association analysis
using SNP alleles/genotypes was undertaken by logistic regression
and included the covariates: age, gender, ethnic group (or ward).
We modelled the SNP of interest assuming several related
genotypic mechanisms (additive, dominant, recessive, heterozy-
gous advantage and general models) and reported the minimum p-
value from these correlated tests. All haplotypes were phased using
an expectation-maximisation algorithm [28]. All analyses were
performed using the R statistical package (http://www.r-project.
org). Performing multiple statistical tests leads to inflation in the
occurrence of false positives and using a permutation approach
that accounted for correlation between markers and tests, we
estimated a p-value of #0.02 to be statistically significant.
Results
Seven SNPs were removed from the analysis because they were
either monomorphic (rs2814778, rs33950507, rs1799969,
rs5743611, rs4986791, X_80140046), deviated from HWE in
controls (rs1800750) or had high rates (.10%) of missing genotype
Figure 1. Severe malaria, Minimum p-values from tests of association for the autosomal SNPs. genotypic tests of dominant, recessive,
general, heterozygous advantage, and additive models, adjusted for HbS and ethnicity; in this analysis controls include uncomplicated malaria cases;
the dashed line represents a p-value of 0.002.
doi:10.1371/journal.pone.0047463.g001
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calls (rs1800750), leaving 58 SNPs which could be analysed for
their association with severe malaria.
Figure 1 shows the minimum p-values from the genotypic tests
applied to the autosomal SNPs, and confirms that the sickle cell
(HbS) polymorphism (rs334) was significantly associated with
protection from severe malaria (odds ratio (OR) AS vs AA/SS
0.055, 95% CI 0.022–0.140, p,3e-18). Carriage of the HbS trait
was also associated with protection from each of the different
clinical phenotypes of severe malaria (Table 2 & Figure 2).
Individuals who had a3.7-thalassaemia deletion (in the additive
model) were 30% less likely than individuals without this
polymorphism to develop severe malarial anaemia (p= 0.01) but
were not significantly protected against other forms of severe
disease. There was no statistical interaction between carriage of
the HbS trait and the a3.7 deletion and risk of any severe malaria
complications (Table 3, p.0.4).
Children carrying either the RTN3 (rs 542998 TC vs. CC OR
1.781, 95% CI 1.276–2.487, p = 0.0006) or the IL-13 (rs 20541
CT vs. TT OR 2.02, 95% CI 1.346–3.03, p = 0.0008) SNPs were
more likely than other children to develop CM (Table 2, Figure 2).
Furthermore, heterozygosity for the rs2230739 SNP in the
ADCY9 gene, encoding an adenylate cyclase, was associated with
a 50% reduction in the risk of acidosis (AG vs. AA/GG,
OR=0.516, 95% CI 0.302–0.882, p= 0.0129) (Table 2, Figure 2).
Two mutations in the G6PD gene on the X chromosome (202:
rs1050828 CT vs. other and 376: rs1050829 CT vs. other) were
strongly associated with protection from severe malaria, and with
protection from each of the different clinical phenotypes of severe
malaria, in heterozygous females (OR=0.3–0.5; p,0.05–p,8e-6)
but not in hemizygous males (Table 2). The protection was best
explained in the dominant model inheritance of the trait
(supplementary Table 2). However, a haplotype analysis using
both G6PD markers (202/376: CT [B - enzymatic group], CC
[A+ deficiency], and TC [A- deficiency]), indicated no strong
evidence of association with protection (P.0.1; supplementary
table 4). Interestingly, polymorphisms in another X-linked gene,
namely that encoding the T cell co-stimulatory receptor CD40
ligand (CD40L; CD154), were associated with either an increased
(rs3092945: OR (TT vs. CT/CC) = 5.27, 95% CI 1.491–18.621,
p = 0.01) or a decreased (rs1126535; OR (TT vs. CT/
CC) = 0.331, 95% CI 0.143–0.766, p = 0.006) risk of respiratory
distress (supplementary table 3). The haplotypic analysis indicates
that having CT haplotypes for rs3092945 and rs1126535 was a
risk of developing respiratory distress in females (OR=1.768,
95%CI 1.027–3.043, p = 0.040; supplementary table 5).
Polymorphisms in three other genes of known immunological
function were also associated with altered risk of severe malaria.
Carriage of the rs17411697 SNP in the gene encoding IL-1a was
associated with an increased risk of acidosis (GT or TT vs. GG,
OR=1.681, 95% CI 1.185–2.382, p = 0.0035), whereas carriage
of the rs1800890 SNP in the IL-10 gene was associated with a
decreased risk of severe malaria (additive T, OR=0.747, 95% CI
0.588–0.949, p = 0.0165) but not with any of the individual severe
malaria syndromes. Carriage of the rs7935564 SNP in the gene
encoding TRIM5 (an E3 ubiquitin-ligase) was associated with an
Figure 2. Severe malaria phenotypes; minimum p-values from tests of association for the autosomal SNPs. genotypic tests of
dominant, recessive, general, heterozygous advantage, and additive models, adjusted for ethnicity; the dashed line represents a p-value of 0.002.
doi:10.1371/journal.pone.0047463.g002
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increased risk of severe malaria (additive A, OR=1.273, 95% CI
1.042–1.555, p = 0.02).
Discussion
We set out to investigate whether genetic polymorphisms
previously linked to altered risk of severe malaria, or implicated in
resistance to other acute infections, were linked to risk of severe
malaria in children living in the Tanga region of Tanzania. For
some of these polymorphisms, there have been discrepancies in
published findings, and these could be a result of variation in
phenotype definition, sample size differences, choice of controls,
village surveys versus hospital-based studies, immune status,
differences in linkage disequilibrium patterns between populations
[29], and potentially functional polymorphisms being distal from
candidate genes and polymorphisms genotyped [30]. To maximise
the robustness of any associations we detected, we standardised
recruitment procedures using case report forms, pre-defined the
criteria for diagnosis of severe malaria and various severe malaria
syndromes. In addition, all analyses were adjusted for the ethnicity
of the child and their ward of residence, thereby minimising
confounding effects and potential false positives arising from
population stratification.
The study confirmed the known (,90%) reduction in severe
malaria risk conferred by the haemoglobin B (sickle cell) AS
genotype [10]. The low frequency of the S allele in the control
children (,4.9%) is in keeping with other populations (see http://
www.map.ox.ac.uk/) in West (Burkina Faso 5.2%, Cameroon
Table 2. Results of association between selected SNP and syndromes of severe malaria.
Phenotype SNP Gene Maj/Min Con MAF CaseMAF Comparison O LCL UCL P
SM rs1800890 IL10 A/T 0.240 0.207 Additive T 0.747 0.588 0.949 0.0165
SM rs334 HBB A/T 0.083 0.016 AT vs. AA/TT 0.055 0.022 0.140 2.28E-18
SM rs7935564 TRIM5 G/A 0.412 0.456 Additive A 1.273 1.042 1.555 0.0176
CM rs334 HBB A/T 0.083 0.000 AT vs. AA/TT 0.000 NA NA 1.35E-07
CM rs542998 RTN3 T/C 0.363 0.495 Additive C 1.781 1.276 2.487 0.0006
CM rs20541 IL13 C/T 0.194 0.324 Additive T 2.020 1.346 3.030 0.0008
SMA Thala thala A/B 0.319 0.251 Additive B 0.703 0.533 0.927 0.0116
SMA rs334 HBB A/T 0.083 0.021 AT vs. AA/TT 0.047 0.011 0.196 3.47E-11
RD rs334 HBB A/T 0.083 0.007 AT vs. AA/TT 0.085 0.020 0.361 2.08E-06
Acid rs334 HBB A/T 0.083 0.012 AT vs. AA/TT 0.021 0.003 0.150 7.07E-14
Acid rs2230739 ADCY9 A/G 0.077 0.057 AG vs. AA/GG 0.516 0.302 0.882 0.0129
Acid rs17411697 IL1A G/T 0.156 0.222 GT/TT vs. GG 1.681 1.185 2.383 0.0035
SM – M rs1050829 G6PD T/C 0.371 0.366 C vs. T 1.003 0.667 1.509 0.9885
SM – F rs1050829 G6PD T/C 0.400 0.340 CT vs. CC/TT 0.437 0.289 0.660 6.71E-05
SM – M rs1050828 G6PD C/T 0.193 0.146 T vs. C 0.770 0.458 1.293 0.3228
SM – F rs1050828 G6PD C/T 0.211 0.174 CT vs. CC/TT 0.514 0.323 0.819 0.0046
SMA – M rs1050829 G6PD T/C 0.371 0.389 C vs. T 1.055 0.643 1.729 0.8325
SMA – F rs1050829 G6PD T/C 0.400 0.295 CT vs. CC/TT 0.278 0.154 0.501 8.64E-06
SMA – M rs1050828 G6PD C/T 0.193 0.170 T vs. C 0.926 0.500 1.713 0.8052
SMA – F rs1050828 G6PD C/T 0.211 0.139 CT vs. CC/TT 0.322 0.159 0.650 0.0008
RD – M rs3092945 CD40LG T/C 0.223 0.189 C vs. T 0.793 0.377 1.667 0.5372
RD – F rs3092945 CD40LG T/C 0.205 0.313 CC vs. CT/TT 5.270 1.491 18.621 0.0096
RD – M rs1126535 CD40LG T/C 0.209 0.237 C vs. T 1.301 0.634 2.670 0.4755
RD – F rs1126535 CD40LG T/C 0.238 0.159 CT vs. CC/TT 0.331 0.143 0.766 0.0062
RD – M rs1050829 G6PD T/C 0.371 0.458 C vs. T 1.369 0.748 2.505 0.3101
RD – F rs1050829 G6PD T/C 0.400 0.352 CT vs. CC/TT 0.308 0.154 0.615 0.0006
RD – M rs1050828 G6PD C/T 0.193 0.203 T vs. C 1.035 0.496 2.160 0.9280
RD – F rs1050828 G6PD C/T 0.211 0.164 CT vs. CC/TT 0.460 0.214 0.989 0.0398
Acid – M rs1050829 G6PD T/C 0.371 0.362 C vs. T 1.024 0.632 1.659 0.9227
Acid – F rs1050829 G6PD T/C 0.400 0.335 CT vs. CC/TT 0.345 0.205 0.580 3.71E-05
Acid – M rs1050828 G6PD C/T 0.193 0.138 T vs. C 0.781 0.419 1.453 0.4319
Acid – F rs1050828 G6PD C/T 0.211 0.158 CT vs. CC/TT 0.495 0.279 0.879 0.0145
SM= severe malaria, SMA= severe malarial anaemia, CM= cerebral malaria, RD= respiratory distress, Acid = acidosis, MinA=minor allele, MajA =major allele,
ConMAF=minor allele frequency in controls, CaseMAF=minor allele frequency in cases, OR = odds ratio, 95% Confidence interval (LCL, UCL), P = P-value; for X
chromosome SNPs (rs1126535 (CD40), rs1050829 (G6PD-376), rs1050828 (G6PD-202/A-), analyses are presented for separately for females (F) and males (M), NA not
applicable, *.
doi:10.1371/journal.pone.0047463.t002
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6.5%, Gambia 7.6%, Ghana 6.5%, Mali 3.8%) and East Africa
(Kenya 6.4%, Malawi 2.7%).
The a+-thalassaemia polymorphism was also associated with
severe malaria anaemia, confirming observations in other studies
[9,31]. This can be explained by the observation that in a-
thalassaemics the mechanical destruction of infected red blood
cells that leads to anaemia is slowed or prevented [32]. Similarly, a
recent study in Papua New Guinea [31] found that homozygous
a+- thalassaemia children are protected from the risk of severe
malarial anaemia by a lower reduction in haemoglobin concen-
tration compared to children of wild-type genotype through
increased erythrocyte count and microcytosis.
The study also confirmed the well-described association
between X-linked G6PD deficiency and protection from severe
malaria. The geographical distribution of G6PD deficiency offers
strong evidence for its selection by malaria; increased oxidative
stress in G6PD-deficient red blood cells is assumed to reduce
parasite replication and thereby confer protection (reviewed in
[8]). Some studies have reported that both hemizygous males and
heterozygous females are protected [33] whereas other studies
suggest either that only male hemizygotes are protected [11,34] or
that, as observed here, protection is limited to female heterozy-
gotes [35]. These discrepancies may be due to allelic/haplotypic
heterogeneity and more detailed resolution of individual alleles will
be required to identify true causal relationships [36].
Interestingly, we found evidence that polymorphisms in another
X-linked gene (CD40L) were associated with altered risk of
respiratory distress, and that a particular CD40L haplotype was
particularly associated with increased disease risk in females. By
contrast, in The Gambia, males hemizygous for the CD40L–726C
(rs17424229) had a reduced risk of developing severe malaria [17].
CD40-L is a stimulatory co-receptor expressed by activated CD4+
T cells, and plays a pivotal role in augmenting T cell mediated
immune function. T cell hypo-responsiveness may predispose to
failure to clear an infection whereas hyper-responsiveness may
lead to immunopathology.
Polymorphism in the adenyl cyclase 9 gene (ADCY9-
rs2230739A.G in a heterozygous model) was associated with
decreased risk of acidosis. Adenyl cyclase 9 is a component of the
stimulatory G protein (Gs) pathway. Inhibition of the Gs signaling
pathway in human erythrocytes blocks merozoite invasion and
inhibits intracellular parasite maturation [37]suggesting that
mutations in genes within this pathway might plausibly be linked
to malaria outcomes [38]. Although there was no evidence that
adenyl cyclase 9 polymorphisms were associated with severe
malaria outcomes in a large study of cases from Malawi and The
Gambia [39], SNPs in two other genes in the Gs signal
transduction pathway - adenosine receptor 2 (ADORA2A) and
G-alpha-s (GNAS) - have been linked to altered risk of severe
malaria in multicentre studies in The Gambia, Malawi and Kenya
[39,40]. Data from studies on chronic acidosis suggest that the
high proton concentrations exerted by acidosis stimulate proton
sensitive G-protein-coupled receptors, which are mediated by the
cellular cAMP/PKA pathway and it is possible that mutations in
Gs would modify this effect [41]. Taken together, these studies
suggest that modulation of the Gs signal transduction pathway
may modulate the outcome of malaria infection. The number of
different associations detected, across different SNPs and loci,
suggest that this pathway may be a biologically relevant modulator
of host susceptibility to malaria.
The role of IL-10 in limiting the pathological consequences of
malaria-induced inflammation is well established (reviewed in
[42]). IL-10 deficient mice infected with normally resolving
malaria infections succumb to acute immunopathology [43], high
ratios of serum IL-10 to proinflammatory cytokines such as IFN-c,
TNF and IL-12 are associated with positive clinical outcomes
[44,45,46] and IL-10-secreting T cells have been correlated with
resistance to severe malaria pathology [47,48]. Furthermore,
polymorphisms involving the IL-10 promoter region have been
associated with both severe malaria outcomes and IL-10
production levels in Kenya [49] and Mozambique [50], and
polymorphisms in the IL-10 receptor gene promoter have also
been linked to protection against severe malaria in Gabon [51],
but the results of a family based study in The Gambia raised
questions as to whether associations with IL-10 signalling
pathways might be confounded by foetal survival rates or other
sources of inheritance bias [26]. Nevertheless, the evidence from
the present study reinforces IL-10 signalling as a pathway of
interest for regulating the severe outcomes of malaria infection.
In this study, carriage of the rs20541C.T polymorphism was
associated with increased risk of developing cerebral malaria; this
polymorphism introduces a nonsynonymous change in exon 4 of
the gene encoding IL-13. In line with the known role of IL-13 in
induction of Th2 responses, rs20541polymorphisms have also
been linked to allergy and autoimmune disease [52,53] as well as
altered outcomes of helminth (Schistosome spp) infections [54].
Our data support other studies implicating IL-13 polymorphisms
with risk of severe malaria in Thai adults [55,56] and associations
between 5q31–q33 haplotypes (which span the IL13 locus) and
antimalarial antibody responses [57]; the recurrent link between
IL-13 and risk of severe malaria would seem to warrant further
investigation.
TRIM5 (an E3 ubiquitin ligase) is an innate immune signalling
molecule that activates pro-inflammatory signalling pathways
leading to activation of NF-kB and AP-1 [58]. Mutations in
TRIM5 have been associated with HIV susceptibility in different
populations (reviewed in [59]), presumably explained by the ability
of TRIM5a to bind HIV virions and target them for proteosomal
destruction [60], but have not previously been linked to malaria
susceptibility.
We observed associations between polymorphisms in reticulon 3
(RTN3- rs542998) and increased risk of cerebral malaria.
Table 3. Interaction between alpha-thalassaema and HbS
and severe malaria.
Phenotype HbS/thal OR** LCL UCL P
SM AA/AA 1.000
SM AA/AB 0.945 0.687 1.301 0.7292
SM AA/BB 0.587 0.342 1.004 0.0517
SM AS/AA 0.115 0.039 0.340 ,0.0001
SM AS/AB 0.092 0.031 0.275 ,0.0001
SM AS/BB 0.115 0.014 0.976 0.0475
SMA AA/AA 1.000
SMA AA/AB 0.779 0.524 1.157 0.2162
SMA AA/BB 0.413 0.203 0.839 0.0145
SMA AS/AA 0.150 0.042 0.528 0.0031
SMA AS/AB 0.126 0.036 0.437 0.0011
SMA AS/BB - - - -
*No significant evidence of a statistical interaction P.0.4, OR =odds ratio, 95%
Confidence interval (LCL, UCL), P = P-value, SM= severe malaria, SMA= severe
malarial anaemia,
**adjusted for age, gender and ethnicity.
doi:10.1371/journal.pone.0047463.t003
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Reticulon 3 is a ubiquitously expressed endoplasmic reticulum
protein and is believed to be involved in membrane trafficking in
the early secretory pathway [61]. It is of interest that RTN3
expression has been repeatedly associated with neurodegenerative
diseases in humans [62] and that RTN3 is differentially expressed
in brains of experimental malaria resistant and susceptible strains
of mice infected with Plasmodium berghei ANKA [63].
Conclusions
This study confirms previously known genetic associations with
protection from severe malaria (HbS, G6PD and a+- thalassae-
mia). The study also identifies two X-linked genes associated with
altered risk of severe malaria in females, identifies mutations in
ADCY9, IL1A and CD40L as being associated with altered risk of
severe respiratory distress and acidosis, both of which are
characterised by high serum lactate levels, and also identifies two
novel (IL-13 and RTN3) genetic associations with cerebral
malaria. The RTN3 and TRIM5 associations draw attention to
the potential role of intracellular protein trafficking and degrada-
tion in the pathogenesis of severe malaria but further studies are
needed in areas of differing malaria epidemiology to replicate
these findings and understand their functional consequences. The
testing of multiple data sets, from diverse malaria endemic regions,
within the MalariaGEN consortium offers a powerful route to
validate these genetic associations [64].
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